Calla M. Olson

Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Cancer Biology, Kinase Inhibition, Cyclin-dependent kinases
"Calla Olson"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Richters A, Doyle SK, Freeman DB, et al. (2020) Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. Cell Chemical Biology
Liu Y, Hao M, Leggett A, et al. (2020) Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13. Journal of Medicinal Chemistry
de Wispelaere M, Carocci M, Burri DJ, et al. (2019) A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation. The Journal of Biological Chemistry
Li Z, Pinch BJ, Olson CM, et al. (2019) Development and Characterization of a Wee1 Kinase Degrader. Cell Chemical Biology
Olson CM, Liang Y, Leggett A, et al. (2019) Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. Cell Chemical Biology
Olson CM, Jiang B, Erb MA, et al. (2017) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology
Kalan S, Amat R, Schachter MM, et al. (2017) Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. Cell Reports. 21: 467-481
Winter GE, Mayer A, Buckley DL, et al. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell
Zhang T, Kwiatkowski N, Olson CM, et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nature Chemical Biology
See more...